FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Parathyroid Hormone Injection
Status: Currently in Shortage
»Date first posted: 09/11/2019
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Takeda Pharmaceuticals USA Inc. (Reverified 04/15/2024)

Company Contact Information:
866-888-0660

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)	Unavailable	Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details – https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/ Dear Healthcare Provider Letter	Discontinuation of the manufacture of the drug
Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)	Unavailable	Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details – https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/ Dear Healthcare Provider Letter	Discontinuation of the manufacture of the drug
Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)	Unavailable	Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired. Please refer to the following link for more details – https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/ Dear Healthcare Provider Letter	Discontinuation of the manufacture of the drug
Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)	Unavailable	The 100 mcg cartridge is no longer available and Takeda is unable to resupply prior to ceasing of manufacturing of Natpara at the end of 2024. Please refer to the following link for more details – https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/ Dear Healthcare Provider Letter	Discontinuation of the manufacture of the drug